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Estimating the size of hidden or difficult to reach populations is often of interest for economic, sociological or
public health reasons. In order to estimate such populations, administrative data lists are often collated to form
multi-list cross-counts and displayed in the form of an incomplete contingency table. Log-linear models are typi-
cally fitted to such data to obtain an estimate of the total population size by estimating the number of individuals
not observed by any of the data-sources. This approach has been taken to estimate the current number of people
who inject drugs (PWID) in Scotland, with the Hepatitis C virus diagnosis database used as one of the data-
sources to identify PWID. However, the Hepatitis C virus diagnosis data-source does not distinguish between
current and former PWID, which, if ignored, will lead to overestimation of the total population size of current
PWID. We extend the standard model-fitting approach to allow for a data-source, which contains a mixture of
target and non-target individuals (i.e. in this case, current and former PWID). We apply the proposed approach
to data for PWID in Scotland in 2003, 2006 and 2009 and compare with the results from standard log-linear
models. © 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.
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1. Introduction
Estimating population sizes using two (or more) data lists has a long history [1]. A number of underlying
assumptions is typically made, including, for example, that individuals are uniquely identifiable by each
data-source, so that individuals can be collated between the different data-sources. The corresponding
data are most often displayed in the form of a contingency table, where each cell corresponds to the
number of individuals observed by each combination of data-sources. However, the table is ‘incomplete’
in that the number of individuals not observed by any of the data-sources is unknown. Here, we distin-
guish our notion of incomplete contingency tables from those that contain structural zeros [2] and those
that are partially classified [3].
Traditionally, log-linear models [4] have been fitted to the observed cells, modelling the probability
of being observed by each cross-classification of data-sources and permitting the estimation of the
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unknown cell count, which can be combined with the total number of observed individuals to pro-
vide an estimate of the total population size. Log-linear models are composed of main-effect terms
and interactions terms between the different data-sources. Typically, the underlying log-linear model is
unknown, and competing models (in terms of the interactions present in the models) can lead to very
different estimates of the total population size. Model discrimination is, therefore, an important com-
ponent of the statistical analysis. Madigan and York [5] and King and Brooks [6] proposed Bayesian
model-averaging approaches, incorporating both parameter and model uncertainty within the estimation
of the total population size.
Log-linear models have been extended to allow additional (discrete) covariates to be incorporated
[7–12]. Specifically, the incomplete contingency table can be extended so that individuals are not only
cross-classified according to the combination of data-sources they are observed by but also according to
the different covariate levels. In such tables, there are multiple unknown cell counts, corresponding to
the number of individuals not observed by any of the data-sources for each cross-classification of pos-
sible covariates. Log-linear models fitted to such data are accordingly extended, allowing for additional
main-effects for each covariate plus interactions between covariates and/or data-sources.
The fact that a cell count of the table is unknown, or missing, may motivate us to consider the missing
data mechanism [13]. This is where the probability of a response being observed (or unobserved) is
considered, including its relationship to the parameters and observed responses. This leads to the terms
missing completely at random, missing at random and missing not at random. Proper consideration
of these mechanisms is important for valid inference. However, in our concept of an incomplete con-
tingency table, the probability of a response being observed (or unobserved) by each combination of
data-sources is actually what we are modelling with log-linear models. For example, an interaction
between two data-sources means that the probability of being observed by one of the data-sources either
increases or decreases depending on whether the other data-source observed the individual.
In this paper, we relax the standard assumption that all individuals recorded by the given data-sources
belong to the population of interest or ‘target’ population. Typically, data-sources are chosen so that they
only observe members of the target population or are able to identify whether an individual is a member
of the target population. However, this may not always be the case. For example, for the data that we
introduce in Section 1.1, we are interested in the current number of people who inject drugs (PWID) in
Scotland. Four data-sources are used to observe such individuals, including the Hepatitis C virus (HCV)
diagnosis database. Individuals are identified as being PWID on this database, but their status as ‘current’
or ‘former’ injector is not recorded. Thus, this data-source records not only current PWID but also
former PWID who do not belong to the target current PWID population of interest. A previous analysis
of one year of these data by King et al. [11] simply discarded the HCV diagnosis database from the set
of data-sources in the analysis. In this paper, we include the HCV diagnosis data-source and explicitly
allow for the fact that not all individuals labelled as PWID by the HCV diagnosis database are members
of the target population of current PWID. We now describe these data in more detail.
1.1. Data
In the last decade, data from multiple administrative data-sources have been repeatedly used to esti-
mate the total number of current PWID in Scotland. We shall consider the data collected in the last
three studies, corresponding to years 2003, 2006 and 2009. Four data-sources were used corresponding
to social enquiry reports (S1), hospital records (S2), Scottish Drug Misuse Database (S3; SDMD) and
HCV diagnosis database (S4). The HCV diagnosis database contains epidemiological data (including
risk group and date of first diagnosis) on all individuals who have been newly diagnosed with HCV in
Scotland. In addition, a range of covariates was recorded for each individual, including age (C1), gen-
der (C2) and region (C3). For each study, age is categorised into two levels (<35 years, 35C years).
For 2003, region was categorised into the two levels, Greater Glasgow and Rest of Scotland, whereas
in 2006 and 2009, the two levels were Greater Glasgow and Clyde, and Rest of Scotland. This change
was to conform with the National Health Service board regions, which altered between the 2003 and
2006 studies. See King et al. [10, 11] for further discussion of the data and for estimation of the current
PWID in Scotland in 2003 and 2006, respectively. Data from the 2009 study have also recently been
made available to the authors. See Table I for summary statistics of the data for all 3 years.
The number of individuals observed by each combination of data-sources and cross-classified across
covariates can be presented in the form of an incomplete 27 contingency table, with 8 (D 23) unknown
cell counts. However, as discussed by [11], the PWID observed by the HCV diagnosis data-source
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Table I. Summary statistics for the data for years 2003, 2006 and 2009 showing
the number of PWID observed in total and by each data-source.
Social enquiry reports Hospital records SDMD HCV diagnosis
Year Total S1 S2 S3 S4
2003 7201 1431 688 5151 761
2006 5670 901 953 3504 827
2009 4967 831 779 2946 888
SDMD, Scottish drug misuse database; HCV, Hepatitis C virus.
are identified by their injecting drug use having been listed as an historical risk factor, which does
not necessarily signify current injecting drug use. In other words, individuals observed by the HCV
diagnosis data-source can be regarded as a combination of former and current PWID. King et al. [10]
assumed that historical injecting drug use corresponded to current drug use for the 2003 data. For the
2006 data, because of an initiative to encourage former PWID, born in 1956–1975, to be tested for
HCV [14–17], King et al. [11] conducted a sensitivity analysis by considering a further analysis exclud-
ing the HCV diagnosis data-source. Excluding the HCV diagnosis data-source resulted in a significant
decrease in the estimated total population size for current PWID from a (model-averaged) posterior
mean of 31 700 (to nearest 100), when using all four data-sources, to 25 000, when excluding the HCV
diagnosis data-source.
1.2. Contributions and outline of paper
In this paper, we investigate, in further detail, the issue of individuals observed by the HCV diagnosis
data-source including both target and non-target individuals. The main contribution of the paper is the
development of a new modelling strategy to incorporate this complexity, without excluding the HCV
diagnosis data-source, and hence, potentially, discarding a significant amount of information. The addi-
tional advantages of this strategy over the approach of [11], of removing the HCV diagnosis data-source,
are that we are able to (i) estimate the proportion of individuals observed by the HCV diagnosis data-
source who are current PWID and (ii) identify interactions between the HCV diagnosis data-source and
the other data-sources and covariates. The results of both of these advantages are of interest to epidemi-
ologists. Using this proposed modelling strategy, we provide, for the first time, estimates of the total
population size of PWID in Scotland for 2009. We also revise the published estimates [10, 11] of the
total population size of PWID for 2003 and 2006, respectively, and for 2003, 2006 and 2009, we provide
estimates of the proportion of individuals observed by the HCV diagnosis data-source who are currently
PWID, for each age group.
The outline of the paper is as follows. Section 2 describes the new modelling strategy in detail and
includes a simulation study to test the strategy’s efficacy. In Section 3, we apply the strategy to the
Scotland PWID multi-list data, for 2003, 2006 and 2009, to provide the aforementioned estimates. We
end with Section 4 discussing future work and epidemiological conclusions of the results in Section 3.
2. Methodology
In this section, we discuss the assumptions relating to the modelling approach before describing
the notation that will be used and the new model-fitting approach to deal with the HCV diagnosis
data-source’s potential for recording both former and current PWID.
2.1. Model formulation and assumptions
We assume that the HCV diagnosis data-source may record individuals from both current and former
PWID (i.e. members of the target and non-target populations, respectively) but that each of the other
data-sources only records current PWID. This implies that individuals recorded by the HCV diagnosis
data-source and any other data-source are a current injector. Thus, only the observed cells corresponding
to being recorded by only the HCV diagnosis data-source (i.e. observed by HCV diagnosis data-source
and unobserved by all other data-sources) for each cross-classification of covariate values may contain
non-target individuals. The corresponding cell entries can then be regarded as an upper bound on the true
cell count (i.e. true number of current PWID observed by only the HCV diagnosis data-source), leading
to left censored cells.
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Notationally, we assume that there n cells in the incomplete contingency table, of which nU are
unobserved and nC are censored. For each year of these data, nD 27 D 128, nU D 23 D 8 (correspond-
ing to being unobserved by each data-source for the 8 covariate cross-classifications) and nC D 23 D 8
(corresponding to being recorded by only the HCV diagnosis data-source for the 8 covariate cross-
classifications). We label each cell from 1; : : : ; n, such that cells i D 1; : : : ; nC correspond to the
censored cells and cells i D nC C 1; : : : ; nC C nU to the unobserved cells. For i D 1; : : : ; n, we let
yi denote the true number of current PWID in cell i . Further, we let yC D fy1; : : : ; ynC g denote the
(true) number of current PWID in the censored cells, yU D fynC C1; : : : ; ynC CnU g the number of cur-
rent PWID in the unobserved cells and yO D fynC CnU C1; : : : ; yng the observed cell entries for the
uncensored cells. Next, we let ´C D f´1; : : : ; ´nC g denote the observed cell entries for the censored
cells. Thus, fyO ; ´C g are the observed data, whereas fyU ;yC g are parameters to be estimated so that
the total population size N D PniD1 yi can be estimated. Finally, we let ˇ denote the set of log-linear
parameters in the model (we return to the issue of model uncertainty later).
We use a special case of a generalised linear model (GLM), where we assume that each (true) cell
count, yi , has an independent Poisson distribution, that is, for i D 1; : : : ; n,
yi jˇ  Poisson.i /; (1)
where i has the form,
logi D xTi ˇ; (2)
such that ˇ denotes the .q C 1/  1 vector of (identifiable) log-linear parameters, ˇ0; ˇ1; : : : ; ˇq , and
xi the .q C 1/  1 design vector relating to cell i D 1; : : : ; n. The term ˇ0 corresponds to the intercept
term, whereas ˇ1; : : : ; ˇq correspond to the main-effect and log-linear interaction terms. For parameter
identifiability, we use the standard sum-to-zero constraints for the log-linear main-effect and interaction
parameters. Because each data-source and covariate only has two levels, each element of xi is equal to
˙1. Finally, we let X denote the n .qC 1/ design matrix with i th row, xi .
An alternative (and equivalent) model specification for y D fy1; : : : ; yng is to set,
yjN;p  Multinomial.N;p/;
where the i th element of p is given by
pi D iPn
jD1 j
; (3)
with i given by Equation (2). This is the model specification considered by [5] and [6] (and subse-
quently [9–11]) assuming no censored cells. This specification allows prior information on the total
population size, N , to be directly incorporated through a prior distribution on N .
2.2. Posterior distribution
Given a log-linear model (in terms of the interaction terms present in the model), the posterior distri-
bution of yU , yC and all model parameters, denoted by  , given the observed data yO and zC , can be
written in the form,
.yU ; yC ;jyO ; zC // .yO jzC ; yU ; yC ;/.zC jyU ; yC ;/.yU ; yC j/./
/ .yj/.zC jyC ;/./; (4)
where y D fyO ;yC ;yU g, and ./ and .j/ represent marginal and conditional probability
density/mass functions, respectively. This result is derived because we assume that the observed cell
entries yO are independent of zC , yU and yC , given ; and the observed censored cells zC are indepen-
dent of yU , given the log-linear parameters  and true cell entries yC . The term .yj/ corresponds
to the complete data likelihood for the full set of cell entries, y , as specified by Equation (1) and
.zC jyC ;/ the distribution of the observed upper bound for the censored cells, given the log-linear
parameters and true cell entries. For these data, we assume non-informative censoring. In other words,
´i jyi  U Œyi ;1/, independently, for i D 1; : : : ; nC (and .zC jyC ;/ D .zC jyC )). In Section 4, we
discuss an alternative distribution for ´i , which can be used to incorporate individual prior information
on the proportion of individuals observed by the HCV diagnosis data-source who are current PWID.
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
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To allow for additional model uncertainty, in terms of the log-linear interaction terms that are
present in the model, we extend the posterior distribution given in Equation (4). We treat the model
indicator as a discrete parameter and form the joint posterior distribution over both parameters and
model space. LetM denote the set of models we wish to consider and let m 2M denote the model
indicator and let m denote the parameters present within modelm 2M. The joint posterior distribution
is given by
.yU ; yC ;m; mjyO ; zC // .yjm; m/.zC jyC /.mjm/.m/; (5)
where .m/ denotes the prior model probability for model m 2M. In this paper, we assume thatM
consists of hierarchical log-linear models [18]. Hierarchical models include, as subsets, the classes of
graphical and decomposable models. These models adhere to the principle of marginality, that is, to
have a higher-order interaction, we need to have all constituent lower-order interactions. Typically, the
simplest (or minimal) model we often consider is the independence model. The independence model has
main-effect terms for all of the data-sources and covariates but no interaction terms. We may also wish
to specify a maximal model, that is, the most complex model we wish to consider, which is performed
by specifying the highest-order interaction.
2.3. Prior distribution
Within the Bayesian approach, we can incorporate any available prior information on the model
parameters, m and m, into the analysis via the prior distributions, .mjm/ and .m/. However,
we assume there is weak prior information on the model parameters and so need to specify a prior
distribution, which reflects this position. In general, care must be taken when specifying prior distribu-
tions on the model parameters under weak prior information in the case of model uncertainty due to
Lindley’s paradox [19] where the posterior model probabilities are sensitive to the scale of the prior
variance for each ˇm. To counter this issue, we use the idea of ‘default prior distributions’ [20], which
aim to provide consistent amounts of prior information under each model, that is, they are compatible
across models. Specifically, we use the generalised hyper g-prior (GHGP), which is an example of a
default prior distribution proposed by Sabanes-Bové and Held [21] for GLMs. To describe this prior
for ˇm, we drop the subscript m, for notational simplicity. Because the intercept, ˇ0, is present in all
models, we assume .ˇ0/ / 1. Let the matrix Y be formed from X by removing the first column of
ones corresponding to ˇ0. The GHGP for the remaining elements, ˛ D .ˇ1; : : : ; ˇq/, of ˇ is given by
˛j2  N 0; 2nYT Y, where 2 > 0 is an unknown hyperparameter. The GHGP extends the Zellner
g-prior [22] for linear models to the wider class of GLMs. The basic idea is that GHGP is the posterior
distribution resulting from an analysis under a locally uniform prior distribution for ˛ and an imaginary
sample of size 1=2, which is referred to as the ‘prior sample size’ by [18]. The unit information prior
for GLMs [23], which is another default prior applicable in this case, is formed by setting 2 D 1, thus
giving a prior sample size of one. This is intuitively appealing because the amount of information the
prior provides is directly interpretable. Sabanes-Bové and Held [21] extended this by letting 1=2 be
unknown by assuming a gamma hyperprior distribution with parameters a=2 and b=2, so that, on the
inverse scale
2  IG

a
2
;
b
2

;
where IG denotes the inverse-gamma distribution. We specify a D b D 103 so that the hyperprior on
1=2 is vague but centred at one. However, in Section 3, we investigate the sensitivity of the resulting
analysis to these values of a and b. The inverse-gamma hyperprior distribution assumed earlier also has
the minor computational advantage of being conditionally conjugate (see step 1 in Section 2.4) meaning
the full conditional distribution of 2 is also an inverse-gamma distribution. Because, in our case, all of
the data-sources and covariates have two levels, under sum-to-zero constraints, the GHGP corresponds
to the elements of ˛ being independent with variance given by 2.
Finally, we specify a uniform prior over all admissible models, that is, .m/ D jMj1, where
jMj is the number of admissible models. However, the computational methods will perform in a
similar fashion for any prior over the model space. The set of parameters for model m is given by
m D fˇm; 2g.
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The joint posterior distribution of yU , yC , m andm under the Poisson specification is identical to that
obtained using the multinomial model formulation when .N//N1, corresponding to Jeffreys’ prior
[5], assuming identical priors on all other parameters and over the model space. This result extends a
result of Forster [24] for complete contingency tables and is proved in Section 1 of the Supporting infor-
mation. Thus, in the presence of no expert prior information (and the Uniform prior on the intercept term
for the Poisson formulation or Jeffreys’ prior on the total population for the multinomial formulation),
the different model specifications are equivalent. However, the Poisson log-linear model specification
is a special case of a GLM, which in turn permits the application of an efficient general computational
algorithm (Section 2.4).
The aim of this paper is to consider the impact of censored contingency cells, and so, to maximise con-
sistency across years, we specify the same default prior from above on the parameters for each dataset.
The previous analyses of the Scotland PWID multi-list data have used the alternative multinomial model
specification in order to specify an informative prior on the total population size,N (obtained by combin-
ing the estimated number of injecting drug related death rates with an estimated associated death rate).
Thus, the posterior distributions for the total population size ignoring the censored cells for 2003 and
2006 will be slightly different to those published in [10] and [11], respectively, because of this different
prior specification.
The priors we have specified earlier are not conjugate. In fact, for hierarchical log-linear models, con-
jugate priors do not exist. This means it is necessary to employ the computational methods, described
in Section 2.4, to evaluate the marginal posterior distribution of the total population size, N . Under the
multinomial model formulation, and for the subset of decomposable models, Madigan and York [5] use
a hyper-Dirichlet distribution [25] on p, which gives a closed form expression for the marginal posterior
distribution of the total population size. However, as Dellaportas and Forster [18] noted, we should not
restrict ourselves to a less flexible class of models for solely computational reasons. In Section 2.5, in a
small simulation study, we compare our approach using hierarchical models to the approach of [5] using
decomposable models.
2.4. Computation
In this section, we describe the computational algorithm used to generate an MCMC sample from the
posterior distribution of yU , yC , m and m, given by Equation (4). The algorithm employed is an
example of data-augmentation and, as such, can be viewed as iterative multiple imputation [3]. The
algorithm has two steps:
Step 1 Conditional on the current values of the unknown and censored cell counts, yU and yC , update
the parameters and model, m and m.
Step 2 Conditional on the current parameters and model, m andm, update the unknown and censored
cell counts, yU and yC .
We consider each step in turn.
Step 1: Updating the parameter and model The log-linear parameters, ˇm, and model, m, are updated
using the reversible jump (RJ) algorithm [26]. Automated RJ algorithms have been proposed for arbitrary
models (see, for example, [27–29]) and specifically for GLMs (see, for example, [18, 30, 31]). We use
the implementation of [31] in which it was shown that the proposed implementation outperformed that
of [18] among other implementations. The technical details are provided in Section 3 of the Supporting
information. This implementation is appropriate where we have specified prior distributions on the model
parameters that reflect weak prior information. Within this RJ algorithm, we also need to specify the ‘null
move’, that is, wherem remains unchanged, and we update only the log-linear parameters, ˇm. Previous
approaches, including the study of King and Brooks [6], typically consider a single-update random walk
Metropolis–Hastings algorithm and use pilot-tuning to obtain the proposal variances [32]. However,
the optimal proposal variance will often depend on the current model m. We use an alternative
algorithm that utilises the iterated weighted least squares implementation of the Metropolis–Hastings
algorithm for GLMs [33]. This algorithm is described for log-linear models in Section 2 of the
Supporting information.
Now consider the hyperparameter, 2. The inverse gamma prior distribution for 2 is conditionally
conjugate so that we update the parameter using the closed form of the full conditional distribution,
that is,
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
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2jy;ˇm  IG
 
aC q
2
;
bCPqjD1 ˇ2j
2
!
; (6)
where ˇm D .ˇ1; : : : ; ˇq/.
Step 2: Updating the cell entries To update the unobserved cell entries yU D fynC C1; : : : ; ynC CnU g,
the full conditional distribution is simply the corresponding Poisson distribution, given in Equation
(1), that is, yi jˇm  Poisson.i /. Similarly, to update the true cell entries for the censored cells,
yC D fy1; : : : ; ynC g, the full posterior conditional distribution is simply a truncated Poisson distribution,
such that yi jˇm; ´i  Poisson.i /I.yi 6 ´i /, where I denotes the indicator function.
The computational approach described in this section is implemented in the R [34] package conting
[35], which is available to download from the Comprehensive R Archive Network. This package includes
the data from 2006.
2.5. Simulation study
In this section, we conduct a small simulation study to assess the efficacy of the proposed modelling
strategy and to compare this against other methods. The simulation study attempts to match the observed
properties of the Scotland PWID multi-list data introduced in Section 1.1 and its inferred properties from
Section 3.
The simulation study is set up as follows. We assume there are four data-sources: S1, S2, S3 and S4,
and that S4 is the censored data-source observing a mixture of individuals from the target and non-target
populations. For simplicity, we assume that there are no covariates. This means that there are 16 cells in
the table. One cell count, yU , is completely unknown; one cell count, yC , is unknown but bounded from
above by ´C ; and the remaining 14 cell counts, yO , are observed. We consider three different true total
population sizes N D 10000; 15000 and 20000. Additionally, we consider two different forms for the
true data-generating model: (i) a model with non-zero interactions for S1 W S2, S1 W S4 and S2 W S4 and
(ii) a model with a non-zero interaction for S1 W S2. Note that model (ii) is decomposable but model (i)
is not decomposable (as it is not even graphical). Table II shows the true values of ˇ under each of the
true data-generating models. These values were chosen so that the simulated data were consistent with
the observed Scotland PWID multi-list data. For example, the negative values of the true parameters
associated with the main-effect terms mean that the probability of observing an individual is less than
that of not observing an individual.
Using the parameter values in Table II and each value of N , we generate the true cell counts from the
multinomial distribution. We remove the cell count, yU , corresponding to not being observed by any of
the data-sources. We also replace yC (the cell count corresponding to just being observed by S4) by ´C ,
where ´C is generated from a negative binomial distribution (under the parameterisation of [36]) with
number of successes yC and probability 2=3 (so as to be consistent with the inferred properties from the
observed data for PWID in Scotland). For each true data-generating model and each true total population
size, we generate 1000 datasets using the aforementioned procedure. We analyse each dataset using the
following four methods.
Table II. True values of the model parameters for the two different true
data-generating models considered in the simulation study in Section 2.5.
Term Parameter Value under model (i) Value under model (ii)
S1 ˇ1 0:75 0:75
S2 ˇ2 0:75 0:75
S3 ˇ3 0:75 0:75
S4 ˇ4 0:75 0:75
S1 W S2 ˇ5 0.25 0.25
S1 W S3 ˇ6 0.00 0.00
S1 W S4 ˇ7 0.25 0.00
S2 W S3 ˇ8 0.00 0.00
S2 W S4 ˇ9 0.25 0.00
S3 W S4 ˇ10 0.00 0.00
Model (i) has three non-zero interactions and model (ii) has one.
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INC-C The proposed modelling strategy, described in Sections 2.1 to 2.4, of incorporating the
censoring mechanism, using hierarchical models.
REM-C The approach of [11] of removing the censored data-source and employing only data-sources
S1, S2 and S3, using hierarchical models.
IGN-C The approach of [10] of ignoring the censoring problem, using hierarchical models.
MY-C The approach of [5], using decomposable models, extended to incorporate the censoring
mechanism.
Note that the MY-C method of [5] does not immediately provide a solution to the censoring problem.
However, we adopt our proposed approach of sampling the true cell count, yC , in the censored cell from
a truncated posterior predictive distribution. Also, note that, to apply the approach of [5], we need to
specify a prior distribution for the total population size, N . To maintain consistency with the three other
approaches listed earlier, we assume Jeffreys’ prior for N , that is, .N//N1 (Section 2.3).
Before we present the results of the simulation study, we briefly contrast the relative advantages and
disadvantages of the four methods. The REM-C and IGN-C methods are the simplest approaches because
we do not model the censoring by either removing the data-source or ignoring the problem altogether,
respectively. The REM-C method will not be able to evaluate the posterior distribution of the proportion,
, of individuals observed by the S4 data-source who are actually members of the target population or
identify interactions involving the S4 data-source. Additionally, for this method, by removing the cen-
sored data-source, we are discarding information. The INC-C and MY-C methods actually model the
censoring mechanism and will be able to provide a posterior distribution of . Additionally, these two
methods can identify interactions involving the S4 data-source. Finally, the INC-C method has the advan-
tage over the MY-C method of considering the much more flexible class of hierarchical models. However,
this advantage comes at the price of requiring more complex computational methods to evaluate the
resulting posterior distributions.
Table III shows the coverage rates and mean lengths (relative to the INC-C method) for 95% highest
posterior density intervals (HPDIs) for the total population size, N , and . These rates and lengths,
averaged over the 1000 datasets, are given for each of the three true values for N , each of the two true
data-generating models and each of the four methods. An entry of NA indicates that this method cannot
Table III. Coverage rates and mean lengths (relative to the INC-C method) of 95% HPDIs
from the simulation study in Section 2.5 for the total population size, N , and the proportion,
, of individuals observed by the S4 data-source who are members of the target population.
Coverage rate (%) Relative mean length
True total Model (i) Model (ii) Model (i) Model (ii)
population size Method N  N  N  N 
10 000 INC-C 93 93 93 95 1.00 1.00 1.00 1.00
REM-C 93 NA 94 NA 1.00 NA 1.02 NA
IGN-C 35 NA 2 NA 1.37 NA 1.06 NA
MY-C 90 88 93 92 1.02 0.98 1.12 1.03
15 000 INC-C 92 94 94 96 1.00 1.00 1.00 1.00
REM-C 92 NA 94 NA 1.00 NA 1.01 NA
IGN-C 26 NA 2 NA 1.49 NA 1.04 NA
MY-C 89 87 92 91 1.03 1.01 1.13 1.06
20 000 INC-C 93 96 95 96 1.00 1.00 1.00 1.00
REM-C 94 NA 94 NA 1.00 NA 1.02 NA
IGN-C 21 NA 1 NA 1.57 NA 1.03 NA
MY-C 89 87 92 91 1.06 1.01 1.18 1.09
The coverage rates and relative mean lengths are given for each true total population size (10 000, 15 000
and 20 000), each true data-generating model (non-zero interactions for (i) S1:S2, S1:S4 and S2:S4 and
(ii) S1:S2) and each of the four methods. Coverage rate refers to the proportion of intervals that contain
the true value of the parameter. The mean length refers to the mean of the difference between the lower
and upper bounds of each interval. An entry of NA indicates that an estimate of this parameter is not
available under this method.
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estimate the value of . Note that the true value of  depends on the true cell counts generated for each
individual dataset.
In terms of coverage, the IGN-C method performs poorly. Further investigation shows that the true
value of N was less than the lower bound of the interval under the IGN-C method for every occurrence
of the interval not covering N . This indicates that the IGN-C method over-estimates the population
size under the chosen two true data-generating models. The remaining methods, INC-C, REM-C and
MY-C, all perform fairly well. As expected, the MY-C method performs in a more satisfactory manner
when the true data-generating model is a decomposable model, that is, for model (ii). The INC-C and
REM-C methods perform very similarly. However, the INC-C method has the advantage of being able to
estimate .
In terms of the mean lengths of the intervals, the INC-C and REM-C methods perform similarly
again with, typically, the INC-C intervals being slightly shorter, that is, more precise. This supports our
intuition, that by removing the censored data-source, we would be discarding information. However, the
actual different in mean lengths between the INC-C and REM-C methods is small. Typically, the MY-C
intervals are slightly wider than the INC-C and REM-C intervals, and this difference is more obvious
under the decomposable model (ii).
We further compare the INC-C, REM-C and IGN-C methods using the Scotland PWID multi-list data
in Section 3.
3. Applying the proposed modelling strategy to the Scotland people who inject
drugs multi-list data in 2003, 2006 and 2009
We apply the proposed methodology (INC-C) from Section 2 to the Scotland PWID multi-list data for
2003, 2006 and 2009. For comparison, we also conduct two additional analyses for each dataset: (i) the
approach of [11] of removing the HCV diagnosis data-source (REM-C) and (ii) the approach of [10] of
ignoring the censoring problem (IGN-C). For all analyses, we assume that the maximal model consists
of the model with all two-way interactions present but no higher-order interactions. This appears to be
sufficient to produce an adequate overall model according to the Pearson-2 statistic and its associated
Bayesian p-value (Section 3.1). In a similar analysis of multi-list data from England, King et al. [12]
found that there was negligible difference in overall population estimates when including higher-order
interactions. For the INC-C and IGN-C (four data-sources) analyses, where the maximal model is as
specified earlier, there will be over two million possible models in M. For the REM-C (three data-
sources) analyses, there will be over 32 000 models. Such large model spaces require large MCMC
sample sizes. For each analysis, the MCMC algorithm was run for two million iterations. MCMC con-
vergence was assessed using trace plots [19] and Geweke’s diagnostic [37] based on the samples from
the posterior distribution of parameters corresponding to the intercept and main effects. In all cases, there
was no evidence of a lack of convergence with the aforementioned MCMC sample size. The exception
to this is for 2009 under the INC-C and REM-C methods. This is due to the posterior distribution for the
total population size being significantly bi-modal with the probabilities of the two modes being compa-
rable. It was decided to run these two chains for five million iterations to obtain more precise estimates
of the relative probabilities of these two modes. The issue of bi-modality of the posterior distribution of
the total population size is discussed in more detail in Section 3.2. Using the R package conting, on
a desktop PC with a quad core 3.20 GHz processor and 16 Gb of memory, two million iterations of the
algorithm for INC-C analyses took between 330 and 340 min, for REM-C between 255 and 265 min and
for IGN-C between 315 and 325 min. The algorithms with five million iterations took proportionately
longer. The acceptance rates for the within-model Metropolis–Hastings moves were for INC-C, between
75% and 80%; for REM-C, between 84% and 86%; and for IGN-C, between 74% and 79%. The accep-
tance rates for the between-model RJ moves were for INC-C, between 6% and 8%; for REM-C, between
4% and 6%; and for IGN-C, between 5% and 8%. For all MCMC chains, the first 10% of the iterations
was discarded as burn-in.
3.1. Assessing model adequacy
In order to assess overall goodness-of-fit of the four data-source analyses, we calculate the (model-
averaged) Bayesian p-value [3] using the Pearson-2 statistic on the observed cell entries, yO , as
the discrepancy function. We take a pragmatic approach whereby a Bayesian p-value in the interval
.0:05; 0:95/ indicates no lack of a goodness-of-fit to the data of the model-averaging approach. For the
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INC-C analyses, we obtain Bayesian p-values of 0.15, 0.44 and 0.30 for years 2003, 2006 and 2009,
respectively; for the IGN-C analyses, values of 0.09, 0.27 and 0.08, respectively; and for the REM-C
analyses, values of 0.06, 0.28 and 0.12, respectively. Thus, for all analyses, the Bayesian p-value sug-
gested an adequate goodness-of-fit for each method. Therefore, these do not suggest that the IGN-C
modelling approach that ignores censoring is inadequate, but these assessments use the same false
assumption as the model does, that is, that all individuals observed by the HCV diagnosis data-source
are current PWID.
3.2. Population estimates
The corresponding posterior estimates for the total population size for current PWID are provided in
Table IV for each analysis, and posterior marginal distributions are displayed graphically in Figure 1.
Table IV. Posterior mean and 95% highest posterior density intervals for the total PWID population
size in Scotland (to nearest 100) for the years 2003, 2006 and 2009 using the INC-C, REM-C and
IGN-C methods.
INC-C REM-C IGN-C
Posterior Posterior Posterior
Year mean 95% HPDI mean 95% HDPI mean 95% HDPI
2003 16 700 (14 300, 20 900) 16 500 (14 200, 20 800) 27 500 (20 700, 32 300)
2006 22 900 (16 300, 27 000) 24 000 (19 500, 29 700) 31 000 (24 600, 37 700)
2009 15 200 (11 500, 18 600) 16 000 (11 500, 19 400) 31 000 (24 000, 38 900)
HPDI, highest posterior density interval.
Figure 1. Plots of the posterior density for the total number of people who inject drugs (PWID) in each year for
the INC-C, REM-C and IGN-C methods.
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
1573
A. M. OVERSTALL ET AL.
Table V. Posterior mean and 95% highest posterior density intervals for the total population size (for INC-C,
REM-C and IGN-C) and the proportion of individuals observed by the Hepatitis C virus diagnosis data-source
who are current people who inject drugs (for INC-C). These posterior estimates are given for each year and
for each age group.
INC-C REM-C IGN-C
Posterior mean Posterior mean Posterior mean Posterior mean
(95% HPDI) (95% HPDI) (95% HPDI) (95% HPDI)
Year for proportion for total population for total population for total population
<35 years
2003 0.62 (0.49, 0.78) 12800 (10900, 16000) 12700 (10800, 16000) 19900 (15100, 23300)
2006 0.68 (0.50, 0.81) 15100 (10800, 17900) 15900 (12700, 19600) 18900 (15000, 23100)
2009 0.58 (0.41, 0.73) 10400 (7800, 12800) 11000 (7800, 13400) 17000 (13100, 21400)
35Cyears
2003 0.46 (0.32, 0.63) 3800 (2800, 5300) 3800 (2700, 5200) 7600 (5500, 9200)
2006 0.51 (0.34, 0.68) 7800 (5300, 10100) 8100 (6000, 10600) 12000 (9000, 15200)
2009 0.22 (0.13, 0.31) 4800 (3600, 6000) 5100 (3600, 6200) 14000 (10200, 17900)
HPDI, highest posterior density interval.
Clearly, the estimates of the total population sizes are significantly larger when analysing the contin-
gency table having ignored the censoring (IGN-C) of the observed cells than when formally modelling
the censored cells (INC-C) or when removing the HCV diagnosis data-source altogether (REM-C). The
INC-C and REM-C analyses provide very similar posterior estimates. Both of these outcomes agree with
the conclusions from the simulation study in Section 2.5.
Figure 1 shows that, for 2003, the posterior distributions all appear to be bi-modal; and in 2009, so too
do the posterior distributions for the REM-C and INC-C analyses (with minor bi-modality in 2006 for
the same analyses). This bi-modality is a result of averaging across different log-linear models. A range
of models is identified with positive posterior support, with some of these models providing reasonably
different estimates of the total population size, leading to the separate smaller sub-modes. In particu-
lar, the separate modes for each year correspond to the inclusion/exclusion of the S1  S3 (social and
SDMD) interaction. For example, for the INC-C analysis for the 2009 data, the posterior probability
of including this interaction is 0.62, contributing to the upper mode of the posterior distribution (with
higher posterior estimates for population size when the interaction is present, because the interaction
has a positive posterior mean). Typically, this interaction (when present) has a positive posterior mean,
with the exception of the 2003 data for INC-C and REM-C. For these analyses, the lower mode corre-
sponds to the inclusion of this parameter (posterior probability of presence: 0.80 and 0.83 for INC-C and
REM-C, respectively).
Table V shows posterior estimates of the total population size (for all three methods) for each age
group. Again, the posterior estimates under the INC-C and REM-C methods are very similar. A peak in
2006 is now clear for the older age group with an approximate doubling in the number of current PWID
between 2003 and 2006 but thereafter a significant fall of the posterior mean from 7800 to 4800 in 2009.
For the younger age group, there appears to be a corresponding fall between 2006 and 2009 (posterior
mean from 15 100 to 10 400) without having seen such a pronounced increase between 2003 and 2006.
3.3. Interactions
Table VI provides the corresponding posterior (marginal) probabilities for each possible interaction
being present in the model for three methods. Note that Table S1 in Section 4 of the Supporting informa-
tion shows the corresponding posterior mean of the log-linear parameters for these interactions. Within
years, the posterior probabilities for the interaction terms are generally consistent in interpretation except
for S1  S2 (social and hospital) and S2  S3 (hospital and SDMD) in 2003; S2  S3 (hospital and
SDMD) and S4  Region (HCV and region) in 2006; S1  S2 (social and hospital), S2  S3 (hospital
and SDMD), S3  Age (SDMD and age) and S4  Region (HCV and region) in 2009.
For 2003 and 2006, the IGN-C analysis lends additional support for a further one interaction terms
being present (i.e. posterior model probability > 0:75); for 2009, a further six interaction terms have
strong positive support, whereas the interaction term S2  S4 (hospital and HCV) loses posterior support.
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Table VI. The marginal posterior probability for each two-way log-linear interaction term for the
INC-C, REM-C and IGN-C methods for the years 2003, 2006 and 2009.
2003 2006 2009
Interaction INC-C REM-C IGN-C INC-C REM-C IGN-C INC-C REM-C IGN-C
S1  S2 0.10 0.10 0.92 0.14 0.10 0.08 0.11 0.16 0.99
S1  S3 0.80 0.83 0.85 0.94 0.99 1.00 0.62 0.79 1.00
S1  S4 0.09 NA 0.15 0.12 NA 0.08 0.33 NA 0.14
S2  S3 0.24 0.22 1.00 0.11 0.11 0.65 0.40 0.27 0.99
S2  S4 1.00 NA 1.00 1.00 NA 1.00 0.94 NA 0.57
S3  S4 0.11 NA 0.17 0.17 NA 0.09 0.12 NA 0.12
S1  Age 1.00 1.00 1.00 1.00 1.00 1.00 0.69 0.67 1.00
S2  Age 0.44 0.48 0.07 0.99 0.98 0.92 1.00 1.00 1.00
S3  Age 0.80 0.76 1.00 1.00 1.00 1.00 0.16 0.16 1.00
S4  Age 0.09 NA 0.12 0.07 NA 0.15 0.32 NA 0.22
S1  Sex 1.00 1.00 1.00 0.08 0.08 0.13 0.07 0.07 0.13
S2  Sex 0.07 0.07 0.06 1.00 1.00 1.00 1.00 1.00 1.00
S3  Sex 0.08 0.08 0.07 0.23 0.05 0.06 0.04 0.04 0.04
S4  Sex 0.11 NA 0.06 0.08 NA 0.13 0.07 NA 0.11
S1  Region 0.93 0.93 0.98 0.21 0.20 0.47 0.07 0.07 0.20
S2  Region 1.00 1.00 1.00 0.05 0.06 0.27 0.04 0.05 0.14
S3  Region 0.06 0.07 0.07 1.00 1.00 1.00 1.00 1.00 1.00
S4  Region 0.98 NA 1.00 0.09 NA 0.82 0.17 NA 1.00
Age  Sex 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Age  Region 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Sex  Region 0.04 0.04 0.02 0.04 0.04 0.04 0.03 0.04 0.03
The data-sources are labelled as S1, social enquiry reports; S2, hospital records; S3, Scottish drug misuse
database (SDMD); and S4, HCV diagnosis data-source. An NA indicates that this interaction cannot be
identified with the REM-C method.
For the interactions identified under the IGN-C method, the sign of the posterior mean of the data-source
 data-source interactions are all positive, which leads to the increased population estimates.
Finally, for all interactions where it is deemed that there is positive evidence that they are present,
except the S1  S3 (social and SDMD) interaction discussed earlier, the sign of the posterior means of
the interactions were consistent across all years and analyses.
3.4. Proportion of individuals observed by the Hepatitis C virus diagnosis data-source who are current
people who inject drugs
As stated, an advantage of the INC-C analysis over the REM-C method is that it allows us now to
consider the proportion of individuals identified by the HCV diagnosis data-source as having a risk
factor of injecting who are actually current PWID (i.e. members of the target population).
Because of the initiative (Section 1.1) to encourage former PWID, born in 1956–1975, to be tested
for HCV diagnosis, we consider the posterior distribution of the proportion of current PWID for the two
different age groups. Table V shows the posterior mean and 95% HPDIs of this proportion for both age
groups for each year. Comparing the two age groups, it appears that the proportion of older individuals
on the HCV diagnosis data-source who are current PWID is lower than for younger individuals. The
largest discrepancy between the age groups is in 2009 where there seems to have been a significant
decrease in the proportion for the older age group compared with 2003 and 2006. This can be compared
with the younger age group, where the proportion appears relatively stable over time. This would support
the hypothesis that, in the older age group, there has been an increase in the number of former PWID
being tested for HCV diagnosis and hence being identified on the HCV diagnosis data-source.
3.5. Prior sensitivity
To investigate the sensitivity of the analysis to the values of the hyperparameters, a and b, which specify
the prior distribution for 2 (Section 2.3), we repeat the INC-C analysis for a range of values of these
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
1575
A. M. OVERSTALL ET AL.
hyperparameters. To do this, we fix aD 0:001 and vary b according to the expectation of the prior sample
size 1=2. We choose b D 0:004; 0:002 and 0:0005 corresponding to expectations of the prior sample
size of 4, 2 and 0.5, respectively. Additionally, we also use the Gelman prior [38], where a uniform prior
(with some suitable large upper bound) is assumed for  so that aD 1 and b D 0 in the full conditional
distribution of 2 given by (6). We compare the resulting posterior mean of the total population size
under each of the four priors to the corresponding posterior mean under the prior specified in Section 2.3
where a D 0:001 and b D 0:001, for each year. In each case, the resulting posterior mean is within 4%
of the corresponding mean for when a D 0:001 and b D 0:001. Note that the posterior means under the
four priors are given in Table S1 of Section 4 of the Supporting information, along with 95% HPDIs.
4. Discussion
Within standard capture-recapture studies, it is assumed that all individuals that are observed by the
data-sources are members of the target population of interest. If this is not the case, the results obtained
can lead to biased population estimates. For the data studied within this analysis, the HCV diagnosis
database identified as PWID those who had listed injecting as their HCV risk factor, thus including
former PWID in addition to the target population of current PWID. In such instances, one possibility
is simply to remove such data-sources from the capture-recapture analyses. However, this may remove
a significant amount of information that is contained within the data-source(s). In this paper, we have
accounted for the possibility of censoring occurring for a single data-source (i.e. a single data-source
may observe non-target individuals) by explicitly accounting for the censoring within the modelling
structure for the HCV diagnosis database.
In particular, we considered estimating the total number of current PWID in Scotland in the years
2003, 2006 and 2009 allowing for censoring for the HCV diagnosis database and compared this with
the analyses that ignored the potential censoring issue or removed the HCV diagnosis database and
considered only three data-sources. Consistently, the analyses that ignored the issue of the HCV diag-
nosis database observing a mixture of former and current PWID led to significantly larger estimates for
the total population size than the other two approaches that accounted for this (either by directly mod-
elling the censoring or simply removing the given data-source). This conclusion was confirmed by the
simulation study in Section 2.5.
The approach of removing the HCV diagnosis data-source produced remarkably similar posterior esti-
mates to that of incorporating the censoring. However, the analysis incorporating censoring allowed us
to estimate the proportion of those present on the HCV diagnosis database with a history of drug use
who are actually current PWID and identify interactions involving the HCV diagnosis data-source. Both
of these are of interest to epidemiologists.
We divide the remainder of this concluding section into two parts. In Section 4.1, we discuss ways
in which the proposed modelling approach that incorporates censoring can be extended by considering
a larger model space,M, and by incorporating informative censoring. In Section 4.2, we discuss the
epidemiological impact of the most up-to-date estimates of the total population size of current PWID
in Scotland in 2009, as well as the revised estimates for 2003 and 2006. Additionally, we also discuss
the impact of the estimates of the proportion of those present on the HCV diagnosis database who are
current PWID.
4.1. Extensions to the proposed modelling approach
In this section, we discuss two ways in which the modelling approach, given in Section 2, can be
extended. First, in Section 3, the maximal model was specified as the model containing all of the
two-way interactions. This gave sufficient complexity to obtain an adequate model according to the
Bayesian p-value. This may not always be the case and we may need to consider a larger set of models,
M, by considering higher-order interactions. In this case, a uniform prior over the model space, that is,
.m/D 1=jMj, is deceptive. When the maximal model only contains two-way interactions and we have
assumed a uniform prior on the model space, the prior probability of each two-way interaction is 1/2.
However, this will not be the case when we consider higher-order interactions, where the prior probabi-
lity of each two-way interaction will be greater than 1/2. We could refine our prior model probabilities
in this case ([39]). The MCMC algorithm described in Section 2.4 would remain unchanged and should
still perform satisfactorily because the RJ implementation employed is based on local proposals and will
be unaffected by changes in the prior model probabilities.
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Second, in this paper, we considered uninformative censoring, that is, the distribution of the upper
bound, ´i , on the censored cell count, yi , for each cross-classification of covariates, is uniform, namely,
´i jyi  U Œyi ;1/ :
We may actually have some prior information on the proportion,  i , of individuals, within each cross-
classification, i , of covariates, observed solely by the HCV diagnosis data-source who are currently
PWID. One way to incorporate this is to assume that
´i jyi ;  i  NB .yi ;  i / ;
where NB denotes the negative binomial distribution [36]. Under this parameterisation of the negative
binomial distribution, ´i is the random variable of the number of trials given yi successes and a proba-
bility of success  i . In this context, the number of trials is the number of individuals observed solely by
the HCV diagnosis data-source and the number of ‘successes’ is the number of current PWID. The prior
information on  i may be in the form of a point estimate or encoded in a prior distribution, for example,
a beta distribution.
4.2. Epidemiological impact
We found that Scotland’s number of current PWID had risen between 2003 and 2006 but decreased
by 2009. This is good news in public health terms but celebration should be cautious because cessa-
tion from injecting need not mean that the individuals concerned have ceased opiate dependency. The
dramatic decrease in Scotland’s number of current PWID between 2006 and 2009, including among
those aged 35C years (Table V), means that there may have been a corresponding increase in the num-
ber of those individuals receiving methadone as an opiate substitution therapy. Scotland’s increase in
older methadone-related deaths in 2011 has been much debated since their publication in mid-August
2012 [40]. In particular, the Scottish Daily Record [41] has called for much better information on the
age-distribution of methadone-clients and to know whether methadone-related deaths occurred in those
to whom methadone was prescribed or diverted. Answers to these questions are all the more important
in view of our results, which strongly suggest that Scotland has reversed the rise in current PWID that
had been apparent in 2006, and that the decrease has come about in both age-groups, although proba-
bly for different reasons. In the younger age group, aversion to injecting, and thereby reduction of new
recruits into injecting [42], may have played a part in addition to cessation from injecting drug use as
a consequence of being recruited into opiate substitution therapy. In the older age group, diagnosis of
HCV carriage while still actively injecting may have been a reason to try to cease injecting both so that
antiviral clearance of HCV carriage would not be undermined by re-infection and also, altruistically,
to avoid onward injection-related HCV transmission. In the older age group, higher age-related risk of
drugs-related death per 100 current PWID may have contributed, and for those who continued to inject
while also receiving opiate substitution therapy, the question of higher risk of methadone-related death
in older individuals is, as yet, unresolved.
Table V provides estimates, by age group, of the proportion of new HCV diagnosed individuals with
historical injecting drug use who were current PWID at the time of their HCV diagnosis: around three-
fifths of those under 35 years of age but a substantially lower proportion, even in 2003 (around 40%), of
those aged 35C years, and by 2009, the proportion had decreased further to 23%.
Finally, the problem of Scotland’s high drug related death rates [43] deepens because, when censoring
is taken into account, we reduce Scotland’s estimated number of current PWID in 2003–2009, and hence,
because the numerator of opiate-related drug related deaths (DRDs) is unchanged, we revise upwards
posterior estimates of opiate-related DRDs per 100 current PWID, in the older age group in particular.
In summary, Scotland, between 2006 and 2009, has both encouraged older former PWID to be
HCV-diagnosed and recorded reductions in its number of current PWID in both age groups (<35 years,
35C years).
Acknowledgements
The authors thank the reviewers and the associate editor for their constructive comments and suggestions, which
have greatly improved the paper. This work was funded by the Medical Research Council-funded addictions
cluster NIQUAD (Grant Number G1000021).
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
1577
A. M. OVERSTALL ET AL.
References
1. Goudie IBJ, Goudie M. Who captures the marks for the Petersen estimator? Journal of the Royal Statistical Society: Series
A 2007; 170:825–839.
2. Mantel N. Incomplete contingency tables. Biometrics 1970; 26:291–304.
3. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis, 2nd edn. Chapman & Hall: Boca Raton, 2004.
4. Fienberg SE. The multiple recapture census for closed populations and incomplete 2k contingency tables. Biometrika
1972; 59:591–603.
5. Madigan D, York JC. Bayesian methods for estimation of the size of a closed population. Biometrika 1997; 84:19–31.
6. King R, Brooks SP. On the Bayesian analysis of population size. Biometrika 2001; 88:317–336.
7. Tilling K, Sterne JAC. Capture-recapture models including covariate effects. American Journal of Epidemiology 1999;
149:392–400.
8. Tilling K, Sterne JAC, Wolfe CD. Estimation of the incidence of stroke using a capture-recapture model including
covariates. International Journal of Epidemiology 2001; 30:1351–1359.
9. King R, Bird SM, Brooks SP, Hutchinson SJ, Hay G. Prior information in behavioural capture-recapture methods:
Demography influences injectors’ propensity to be listed on data-sources and their drugs-related mortality. American
Journal of Epidemiology 2005; 162:694–703.
10. King R, Bird SM, Hay G, Hutchinson S. Estimating current injectors in Scotland and their drug-related death rate
by sex, region and age-group via Bayesian capture-recapture methods. Statistical Methods in Medical Research 2009;
18:341–359.
11. King R, Bird SM, Overstall AM, Hay G, Hutchinson SJ. Injecting drug users in Scotland, 2006: Listing, number,
demography, and opiate-related death-rates. Addiction Research and Theory 2013a; 21:235–246.
12. King R, Bird SM, Overstall AM, Hay G, Hutchinson SJ. Estimating prevalence of injecting drug users and associated
death rates in England using regional data and incorporating prior information. Journal of the Royal Statistical Society:
Series A 2013b. in press.
13. Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. Wiley: New Jersey, 2002.
14. Edinburgh Royal College of Physicians. Hepatitis C Consensus Conference, Edinburgh Royal College of Physicians, 2004.
Available at http://www.rcpe.ac.uk/clinical-standards/standards/hep_c_04.php.
15. Hutchinson SJ, Bird SM, Goldberg DJ. Modelling the current and future disease burden of Hepatitis C among injecting
drug users in Scotland. Hepatology 2005; 42:711–723.
16. The Scottish Government. Hepatitis C Action Plan for Scotland Phase I: April 2006 - March 2008, The Scottish
Government Edinburgh 2006, 2006. (Available at URL: http://www.scotland.gov.uk/Resource/Doc/148746/0039553.pdf).
17. Bird SM, Robertson R, Beresford H, Hutchinson SJ. Targets for Hepatitis C virus test uptake and case-finding among
injecting drug users: in prisons and general practice. Addiction Research and Theory 2010; 18:421–432.
18. Dellaportas P, Forster JJ. Markov chain Monte Carlo model determination for hierarchical and graphical log-linear models.
Biometrika 1999; 86:615–633.
19. O’Hagan A, Forster JJ. Kendall’s Advanced Theory of Statistics, Volume 2B: Bayesian Inference, 2nd edn. Arnold: London,
2004.
20. Kass RE, Wasserman L. The selection of prior distributions by formal rules. Journal of the American Statistical
Association 1996; 91:1343–1370.
21. Sabanes-Bové D, Held L. Hyper-g priors for generalized linear models. Bayesian Analysis 2011; 6:387–410.
22. Zellner A. On assessing prior distributions and Bayesian regression analysis with g-prior distributions. In Bayesian
Inference and Decision Techniques: Essays in Honor of Bruno de Finetti, Goel PK, Zellner A (eds). North-Holland:
Amsterdam, 1986; 233–243.
23. Ntzoufras I, Dellaportas P, Forster JJ. Bayesian variable and link determination for generalised linear models. Journal of
Statistical Planning and Inference 2003; 111:165–180.
24. Forster JJ. Bayesian inference for Poisson and multinomial log-linear models. Statistical Methodology 2010; 7:
210–224.
25. Dawid AP, Lauritzen SL. Hyper markov laws in the statistical analysis of decomposable graphical models for contingency
tables. The Annals of Statistics 1993; 21:1272–1317.
26. Green PJ. Reversible jump Markov chain Monte Carlo computation and Bayesian model determination. Biometrika 1995;
82:711–732.
27. Brooks SP, Giudici P, Roberts GO. Efficient construction of reversible jump Markov chain Monte Carlo proposal
distributions. Journal of the Royal Statistical Society, Series B 2003; 65:3–55.
28. Green PJ. Trans-dimensional Markov chain Monte Carlo. In Highly Structured Stochastic Systems, Green PJ, Hjort NL,
Richardson S (eds). Oxford University Press: Oxford, 2003; 179–198.
29. Fan Y, Peters GW, Sisson SA. Automating and evaluating reversible jump MCMC proposal distributions. Statistics and
Computing 2009; 19:402–421.
30. Papathomas M, Dellaportas P, Vasdekis VGS. A novel reversible jump algorithm for generalized linear models. Biometrika
2011; 98:231–236.
31. Forster JJ, Gill RC, Overstall AM. Reversible jump methods for generalised linear models and generalised linear mixed
models. Statistics and Computing 2012; 22:107–120.
32. Roberts GO, Rosenthal JS. Optimal scaling for various Metropolis–Hastings algorithms. Statistical Science 2001;
16:351–367.
33. Gamerman D. Sampling from the posterior distribution in generalised linear mixed models. Statistics and Computing
1997; 7:57–68.
34. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2013.
ISBN 3-900051-07-0, http://www.R-project.org/.
1578
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
A. M. OVERSTALL ET AL.
35. Overstall AM. Conting: Bayesian Analysis of Contingency Tables. R package version 1.1, 2013. http://CRAN.
R-project.org/package=conting.
36. Mendenhall W, Wackerly DD, Scheaffer RL. Mathematical Statistics with Applications, 4th edn: London, Duxbury, 1990.
37. Geweke J. Evaluating the accuracy of sampling-based approaches to calculating posterior moments. In Bayesian Statistics
4, Bernado JM, Berger JO, Dawid AP, Smith AFM (eds). Oxford Press, 1992; 169–193.
38. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 2006; 1:515–533.
39. Chipman H, George EI, McCulloch RE. The practical implementation of Bayesian model selection. In Model Selection,
Lahiri P (ed.). IMS: CA, 2001; 65–116.
40. National Records of Scotland. Drug-related deaths in Scotland in 2011, National Records of Scotland, 2012. (Available at
http://www.gro-scotland.gov.uk/files2/stats/drug-related-deaths/2011/drug-related-deaths2011.pdf).
41. Ferguson J, Clegg D. Methadone probe launched by Scottish Government after Daily Record reveals 36m-a-year heroin
substitute scandal. Scottish Daily Record 2012.
42. White SR, Taylor A, Allen E, Hutchinson SJ, Bird SM. Modelling the initiation of others into injecting drug use, using
data from 2,500 injectors surveyed in Scotland during 2008-09. Technical Report, MRC Biostatistics Unit Cambridge,
2012.
43. Bird SM, Hutchinson SJ, Hay G, King R. Commentary: missing targets on drugs-related deaths, and a Scottish paradox.
International Journal of Drug Policy 2010; 21:155–159.
Supporting Information
Additional supporting information may be found in the online version of this article at the publisher’s
web site.
© 2013 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1564–1579
1579
